Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 257

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 257
---
 is a wholly owned subsidiary of Bristol-Myers Squibb Company (“BMS”).

In November 2021, the U.S. Food and Drug
Administration (the “FDA”) approved FYARRO sirolimus protein-bound particles for injectable suspension (albumin-bound) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid
cell tumor (“PEComa”). On February 22, 2022, we launched FYARRO in the United States for treatment of advanced malignant PEComa and recognized net product sales of $7.2 million and $18.7 million for the three and nine months
ended September 30, 2024, respectively. See “Results of Consolidated Operations” for further discussion of our results.

We recently
entered into the License Agreement, an intellectual property license agreement with WuXi Biologics, for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (ADCs) targeting clinically
validated, broadly overexpressed tumor antigens in high potential

- 178 -

cancer indications with significant unmet need. The License Agreement is described further below. These ADCs are constructed utilizing an advanced linker-payload platform called CPT113 that has been shown to provide high stability in blood circulation and deliver targeted release of a Topoisomerase I (TOPO1) inhibitor payload into cancer cells. Recent Developments

| • |     | Divestiture of FYARRO. On December 19, 2024, we entered into a Stock Purchase Agreement (the                                                                                                                                                    
 “Divestiture Agreement”) with KAKEN INVESTMENTS INC. (“Kaken”) for the sale to Kaken of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. (“Aadi Sub”) and thereby all of Aadi’s assets related                          
 to its FYARRO® (sirolimus protein-bound particles for injectable suspension) (albumin-bound) program (the “FYARRO Business”), which may be deemed to be a sale of substantially all of                                                          
 Aadi’s assets under Section 271 of the Delaware General Corporation Law, as amended. Per the terms and subject to the conditions of the Divestiture Agreement, Kaken will pay Aadi $100 million in cash at closing, subject to certain          
 adjustments. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval